Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, IRBLleida, University of Lleida, Lleida, Spain.
Semin Respir Crit Care Med. 2022 Aug;43(4):570-582. doi: 10.1055/s-0042-1748186. Epub 2022 Sep 14.
Although the potential causes of nonmalignant pleural effusions are many, the management of a few, including complicated pleural infections and refractory heart failure and hepatic hydrothoraces, can be challenging and requires the assistance of interventional pulmonologists. A pragmatic approach to complicated parapneumonic effusions or empyemas is the insertion of a small-bore chest tube (e.g., 14-16 Fr) through which fibrinolytics (e.g., urokinase and alteplase) and DNase are administered in combination. Therapeutic thoracenteses are usually reserved for small to moderate effusions that are expected to be completely aspirated at a single time, whereas video-assisted thoracic surgery should be considered after failure of intrapleural enzyme therapy. Refractory cardiac and liver-induced pleural effusions portend a poor prognosis. In cases of heart failure-related effusions, therapeutic thoracentesis is the first-line palliative therapy. However, if it is frequently needed, an indwelling pleural catheter (IPC) is recommended. In patients with hepatic hydrothorax, repeated therapeutic thoracenteses are commonly performed while a multidisciplinary decision on the most appropriate definitive management is taken. The percutaneous creation of a portosystemic shunt may be used as a bridge to liver transplantation or as a potential definitive therapy in nontransplant candidates. In general, an IPC should be avoided because of the high risk of complications, particularly infections, that may jeopardize candidacy for liver transplantation. Even so, in noncandidates for liver transplant or surgical correction of diaphragmatic defects, IPC is a therapeutic option as valid as serial thoracenteses.
虽然非恶性胸腔积液的潜在病因很多,但少数病因的治疗具有挑战性,需要介入肺科医生的协助,这些病因包括复杂的胸膜感染以及难治性心力衰竭和肝性胸水。对于复杂的类肺炎性胸腔积液或脓胸,实用的处理方法是通过插入小口径胸管(例如 14-16Fr),联合应用纤维蛋白溶解剂(例如尿激酶和阿替普酶)和 DNA 酶。治疗性胸腔穿刺术通常保留用于预计可在单次抽吸时完全清除的小至中等量胸腔积液,而在胸膜腔内酶治疗失败后应考虑采用电视辅助胸腔手术。难治性心脏和肝脏引起的胸腔积液预示预后不良。在心衰相关胸腔积液的情况下,治疗性胸腔穿刺术是一线姑息性治疗。然而,如果需要频繁进行,则建议使用留置胸腔导管(IPC)。对于肝性胸水患者,通常会反复进行治疗性胸腔穿刺术,同时针对最合适的确定性治疗方案做出多学科决策。经皮创建门体分流术可作为肝移植的桥梁,也可作为非移植候选者的潜在确定性治疗方法。一般来说,由于并发症风险高,特别是感染可能危及肝移植候选资格,应避免使用 IPC。即便如此,对于不能进行肝移植或膈疝手术矫正的患者,IPC 是与反复胸腔穿刺术一样有效的治疗选择。